Paun B, Schüler A
Bergman Clinics Augenklinik Universitätsallee, Parkallee 301, 28213, Bremen, Deutschland.
Ophthalmologie. 2023 Feb;120(2):184-190. doi: 10.1007/s00347-022-01714-3. Epub 2022 Aug 26.
There is no standard for the treatment of functional aphakia in cases with a compromised capsular system. Retropupillary fixation of an Artisan iris-claw IOL ("Intraokularlinse") is one of the established procedures.
Aim of this study was the evaluation of indications, visual and refractive long-term results and complication rates after retropupillary implantation of an iris-claw lens.
This retrospective study comprised 366 eyes that received a retropupillary Artisan intraocular lens (IOL) in a single center between January 2009 and December 2019. The mean follow-up period was 249 days (8 months) ±516 days.
IOL dislocation (68%) was the most common reason for a retropupillary iris-claw implantation. Previous vitrectomy was a significant preoperative risk factor for IOL dislocation (p = 0.0001). Best corrected visual acuity improved from 0.65 ± 0.64 (logMAR) preoperatively to 0.57 ± 0.51 (logMAR) 4-6 weeks after the surgery. The mean deviation from the planned refraction was +0.40 ± 1.37 dpt and 73% of the patients had a deviation within ±1 dpt of the planned refraction. Relevant postoperative complications during the first 4 weeks were pupillary distortion (42%), ocular hypotony (15%) and transient hyphema (14%). Late complications (≥4 weeks after the surgery) included persistent pupillary distortion (20%), cystoid macular edema (13%) and iris-claw disenclavation (6%).
The retropupillary Artisan implantation is an efficient method for treating aphakia without capsular support and provides good visual and refractive results with an acceptable surgical risk profile.
对于囊膜系统受损的无晶状体眼病例,目前尚无功能性无晶状体眼的治疗标准。Artisan虹膜爪型人工晶状体(“眼内晶状体”)的瞳孔后固定是既定的手术方法之一。
本研究的目的是评估虹膜爪型晶状体瞳孔后植入后的适应症、视觉和屈光长期结果以及并发症发生率。
这项回顾性研究纳入了2009年1月至2019年12月在单一中心接受瞳孔后Artisan人工晶状体(IOL)植入的366只眼。平均随访期为249天(8个月)±516天。
人工晶状体脱位(68%)是瞳孔后虹膜爪植入最常见的原因。既往玻璃体切除术是人工晶状体脱位的一个重要术前危险因素(p = 0.0001)。最佳矫正视力从术前的0.65±0.64(logMAR)提高到术后4 - 6周的0.57±0.51(logMAR)。与计划屈光度的平均偏差为+0.40±1.37屈光度,73%的患者偏差在计划屈光度的±1屈光度范围内。术后前4周的相关并发症包括瞳孔变形(42%)、低眼压(15%)和短暂性前房积血(14%)。晚期并发症(术后≥4周)包括持续性瞳孔变形(20%)、黄斑囊样水肿(13%)和虹膜爪脱离(6%)。
瞳孔后Artisan人工晶状体植入是治疗无囊膜支持的无晶状体眼的有效方法,能提供良好的视觉和屈光效果,且手术风险可接受。